After years of robust growth driven by a coach-led direct-to-consumer model, Medifast encountered a significant inflection point in fiscal year 2025 with declining revenues and operating losses. The surge in pharmaceutical weight loss medications, particularly GLP-1 drugs, alongside macroeconomic pressures, disrupted its traditional momentum. The company’s strategic pivot toward a broader metabolic health framework aims to leverage its clinical heritage and coaching flywheel to rebuild growth, but near-term financial metrics reflect profitability challenges and subdued cash flow. Monitoring coach productivity, client retention, and new product adoption will be critical milestones to gauge Medifast’s recovery trajectory.